Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor. The PCM-075 is in Phase Ib/II clinical trial in acute myeloid leukemia (AML) and has completed a Phase I clinical trial in advanced solid tumors.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone858-952-7570
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$380,000.00
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
TrovaGene (NASDAQ:TROV) Frequently Asked Questions
What is TrovaGene's stock symbol?
TrovaGene trades on the NASDAQ under the ticker symbol "TROV."
When did TrovaGene's stock split? How did TrovaGene's stock split work?
TrovaGene shares reverse split before market open on Wednesday, February 20th 2019. The 1-6 reverse split was announced on Tuesday, February 19th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 19th 2019. An investor that had 100 shares of TrovaGene stock prior to the reverse split would have 17 shares after the split.
How were TrovaGene's earnings last quarter?
TrovaGene Inc (NASDAQ:TROV) released its quarterly earnings data on Thursday, August, 8th. The medical research company reported ($0.79) EPS for the quarter, missing the Zacks' consensus estimate of ($0.52) by $0.27. The medical research company had revenue of $0.14 million for the quarter. TrovaGene had a negative net margin of 3,424.46% and a negative return on equity of 149.88%. View TrovaGene's Earnings History.
When is TrovaGene's next earnings date?
What price target have analysts set for TROV?
2 analysts have issued 12-month price targets for TrovaGene's shares. Their forecasts range from $6.00 to $23.00. On average, they expect TrovaGene's share price to reach $14.50 in the next twelve months. This suggests a possible upside of 1,281.0% from the stock's current price. View Analyst Price Targets for TrovaGene.
What is the consensus analysts' recommendation for TrovaGene?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TrovaGene in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TrovaGene.
What are Wall Street analysts saying about TrovaGene stock?
Here are some recent quotes from research analysts about TrovaGene stock:
- 1. Maxim Group analysts commented, "Trovagene reported 2Q19 with a net loss of ($4.1M) and ended the period with $10.8M in cash on the balance sheet." (8/9/2019)
- 2. According to Zacks Investment Research, "Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA. Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. " (5/9/2019)
Has TrovaGene been receiving favorable news coverage?
Media headlines about TROV stock have been trending somewhat positive on Saturday, according to InfoTrie Sentiment. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. TrovaGene earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for TrovaGene.
Are investors shorting TrovaGene?
TrovaGene saw a decline in short interest during the month of September. As of September 15th, there was short interest totalling 454,100 shares, a decline of 23.2% from the August 15th total of 591,300 shares. Based on an average trading volume of 288,100 shares, the days-to-cover ratio is currently 1.6 days. Currently, 7.4% of the company's stock are sold short. View TrovaGene's Current Options Chain.
Who are some of TrovaGene's key competitors?
Some companies that are related to TrovaGene include Entera Bio (ENTX), Microbot Medical (MBOT), aTyr Pharma (LIFE), Enzon Pharmaceuticals (ENZN), Genetic Technologies (GENE), CytRx (CYTR), TRACON Pharmaceuticals (TCON), Aevi Genomic Medicine (GNMX), Vaxart (VXRT), Proteon Therapeutics (PRTO), Vitro Diagnostics (VODG), Titan Pharmaceuticals (TTNP), Neuralstem (CUR), Gene Biotherapeutics (CRXM) and AIM ImmunoTech (AIM).
What other stocks do shareholders of TrovaGene own?
Who are TrovaGene's key executives?
TrovaGene's management team includes the folowing people:
- Dr. Thomas H. Adams, CEO & Exec. Chairman (Age 76)
- Dr. Mark Erlander, Chief Scientific Officer (Age 59)
- Ms. Elizabeth Anderson, VP of Fin. & Admin.
- Mr. George Samuel, VP & Gen. Counsel
- Ms. Vicki Kelemen, VP of Corp. Communications
How do I buy shares of TrovaGene?
Shares of TROV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is TrovaGene's stock price today?
One share of TROV stock can currently be purchased for approximately $1.05.
How big of a company is TrovaGene?
TrovaGene has a market capitalization of $6.49 million and generates $380,000.00 in revenue each year. The medical research company earns $-16,460,000.00 in net income (profit) each year or ($8.26) on an earnings per share basis. View Additional Information About TrovaGene.
What is TrovaGene's official website?
How can I contact TrovaGene?
TrovaGene's mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The medical research company can be reached via phone at 858-952-7570 or via email at [email protected]
MarketBeat Community Rating for TrovaGene (NASDAQ TROV)
MarketBeat's community ratings are surveys of what our community members think about TrovaGene and other stocks. Vote "Outperform" if you believe TROV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TROV will underperform the S&P 500 over the long term. You may vote once every thirty days.
